

Congress Agenda

Title:

Advances in Keratinocytic
Precancer Management

Objective:

1st International Actinic
Keratoses (AK) Congress


Date:

29 January 2027


Time:

09:00 – 17:15


Venue:

kHaus, Kasernenstrasse 8,
Basel, Switzerland


Scientific Committee

Prof. Lasse R. Braathen, Prof. Günther Hofbauer, Prof. Alexander Navarini,
Prof. Rolf-Markus Szeimies, Prof. Colin Morton

08:30 – 09:00 Registration & Coffee

09:00 – 09:10 Welcome & Introduction

Session 1:
Clinical spectrum, pathology and risk of progression

Chairs: Prof. Lasse R. Braathen & Prof. Alexander Navarini

- 09:10 – 09:30 Actinic keratosis: epidemiology, clinical spectrum and burden of disease
- 09:30 – 09:50 Field cancerisation: concept, biology and clinical implications
- 09:50 – 10:10 Histopathology of actinic keratosis and keratinocytic intraepithelial neoplasia
- 10:10 – 10:30 The PRO score: can we predict which AK will progress?

10:30 – 11:00 Coffee break & Networking

Session 2:
Evidence-based treatment strategies

Chairs: Prof. Colin Morton & Prof. Rolf-Markus Szeimies

- 11:00 – 11:20 Lesion-directed therapies: cryotherapy, curettage and office-based approaches
- 11:20 – 11:35 Field-directed therapies: what do the meta-analyses really tell us?
- 11:35 – 11:50 Photodynamic therapy and daylight PDT: current role and patient selection
- 11:50 – 12:05 TBA
- 12:05 – 12:20 Enhancement of PDT by pretreatment (Laser, other)
- 12:20 – 12:40 AI meets actinic keratosis: LC-OCT-guided precision management

12:40 – 14:00 Lunch break & Networking

Congress Agenda

Title:

Advances in Keratinocytic
Precancer Management

Objective:

1st International Actinic
Keratoses (AK) Congress



Date:
29 January 2027



Time:
09:00 – 17:15



Venue:
kHaus, Kasernenstrasse 8,
Basel, Switzerland



Scientific Committee

Prof. Lasse R. Braathen, Prof. Günther Hofbauer, Prof. Alexander Navarini,
Prof. Rolf-Markus Szeimies, Prof. Colin Morton

Session 3:

Guidelines, special populations and mechanism-targeted prevention

Chairs: Prof. Markus Heppt & Prof. Günther Hofbauer

- 14:00 – 14:20 European and international guidelines: where do we agree, where do we differ?
- 14:00 – 14:20 Personalised treatment selection: site, field damage, adherence and patient preference
- 14:40 – 14:50 Topical rapamycin as a new option in the treatment of actinic keratosis
- 14:50 – 15:00 Topical bimiralisib: dual PI3K/mTOR inhibition in actinic keratosis
- 15:00 – 15:10 Treatment by collateral? AK during checkpoint inhibition
- 15:10 – 15:20 Microbioma and actinic keratosis Jan Buer

15:20 – 15:50 Coffee break & Networking

Session 4:

Controversies, case discussions and outlook

Chairs: Prof. Lasse R. Braathen & Prof. Alexander Navarini

- 15:50 – 16:10 Controversy: Actinic keratosis — cancer or not?
- 16:10 – 16:50 Case-based expert discussion
- 16:50 – 17:00 Photodynamic therapy and daylight PDT: current role and patient selection
- 17:00 – 17:10 Closing remarks and take-home messages

17:10 – 17:15 Farewell